Does MDwise Cover Prolia (Denosumab)?

What MDwise Is and Why It Controls Your Prolia Coverage

MDwise is one of Indiana's contracted Medicaid managed care organizations. The Indiana Family and Social Services Administration (FSSA) delegates pharmacy and medical benefit management to MCOs like MDwise, which means MDwise sets its own formulary and prior authorization (PA) criteria within state-defined guardrails.

MDwise as an MCO

Prolia is administered as a subcutaneous injection in a clinical setting every six months. Because of that delivery route, it may fall under the medical benefit (billed as a physician-administered drug) rather than the pharmacy benefit, depending on whether the prescriber gives the injection in-office or refers to an infusion center. Which benefit bucket applies changes the PA pathway, so confirming this with the prescribing provider before submitting paperwork saves significant time.

Indiana Medicaid mandates that MCOs cover medically necessary services consistent with federal Medicaid law under 42 U.S.C. § 1396 and CMS guidance. Prolia has FDA approval for postmenopausal osteoporosis, glucocorticoid-induced osteoporosis (GIOP), and bone loss in men receiving androgen deprivation therapy (ADT) or women receiving adjuvant aromatase inhibitor therapy for breast cancer. Each of these indications carries its own clinical documentation requirements.

Why Prior Authorization Exists for Prolia

Denosumab is a RANK ligand inhibitor. It works by binding RANKL, blocking osteoclast formation, and reducing bone resorption. The key FREEDOM trial (N=7,868) showed denosumab reduced new vertebral fracture risk by 68%, hip fracture risk by 40%, and nonvertebral fracture risk by 20% over 36 months versus placebo. Those results are strong, but the drug costs roughly $3,800, $4,400 per year at list price. Insurers, including Medicaid MCOs, require PA to confirm the clinical indication is solid before approving that expenditure.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state that denosumab is a first-line option for patients at "very high fracture risk," defined as a T-score at or below -3.0, a recent fracture within 12 months, or a FRAX 10-year major osteoporotic fracture probability above 30% (AACE/ACE Clinical Practice Guidelines, Endocr Pract. 2020). MDwise's PA criteria generally align with these thresholds, though the plan's specific language can differ slightly from year to year.

Prolia's FDA-Approved Indications Relevant to MDwise Coverage

Understanding exactly what the FDA approved helps when framing a PA request or an appeal. Coverage is anchored to labeled indications.

Postmenopausal Osteoporosis

The FDA approved Prolia on June 1, 2010, for treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The FDA prescribing information specifies the approved dose as 60 mg subcutaneously once every six months.

In the FREEDOM trial, vertebral fracture incidence over 36 months was 2.3% in the denosumab group versus 7.2% in the placebo group, an absolute risk reduction of 4.9 percentage points (Cummings SR et al., NEJM 2009). MDwise reviewers are familiar with this data; citing it directly in a PA letter strengthens the request.

Glucocorticoid-Induced Osteoporosis

Patients taking 7.5 mg or more of prednisone (or equivalent) daily for six months or longer face accelerated bone loss. The FDA extended Prolia's label to include GIOP in adults at high fracture risk in 2018. A randomized trial published in NEJM (Saag KG et al., 2019, N=795) showed denosumab increased lumbar spine BMD by 4.4% versus 3.7% for risedronate at 12 months (P<0.001). For MDwise PA in GIOP, documentation should include current steroid dose, duration, and a recent DXA scan.

Male Osteoporosis and Oncology Indications

Prolia is also FDA-approved for osteoporosis in men at high fracture risk and for bone loss associated with ADT in men with nonmetastatic prostate cancer and with adjuvant aromatase inhibitor therapy in women with breast cancer. These oncology-adjacent indications can face additional scrutiny from MDwise because they sit at the intersection of oncology and metabolic bone disease benefit categories.

MDwise Prior Authorization Requirements for Prolia

MDwise does not publish its full PA criteria on a freely accessible public-facing page the way some commercial plans do. However, Indiana Medicaid MCO PA criteria must be available upon request under state law, and the following requirements are consistently seen in practice across Indiana Medicaid MCOs including MDwise.

Required Clinical Documentation

A complete PA submission for Prolia through MDwise typically needs:

• A recent DXA (dual-energy X-ray absorptiometry) scan report showing T-score at or below -2.5 (osteoporosis) or -2.0 with additional fracture risk factors
• Prescriber documentation of the clinical indication (postmenopausal osteoporosis, GIOP, male osteoporosis, or an oncology indication)
• Evidence of intolerance or contraindication to bisphosphonates, OR documented trial of an oral bisphosphonate for at least 6 to 12 months with inadequate response
• Current medication list confirming calcium and vitamin D supplementation (500 to 1,200 mg calcium daily and 800 to 2,000 IU vitamin D3 daily, per NIH Office of Dietary Supplements guidance)
• Lab values: serum calcium must be within normal limits before each injection because denosumab can cause hypocalcemia; the FDA label carries a specific warning about this

Step Therapy: Bisphosphonates First

Step therapy is the most common reason Prolia gets denied on first submission. MDwise, like most Medicaid MCOs, considers alendronate (generic, $5, $20/month at Indiana pharmacies) and risedronate the preferred first-line agents for osteoporosis. The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) Clinician's Guide recommends bisphosphonates as first-line due to their long safety record and low cost, which underpins formulary hierarchy decisions.

Bisphosphonate contraindications that justify skipping step therapy include: estimated GFR below 35 mL/min/1.73m² (a threshold where oral bisphosphonates are generally avoided), active esophageal disease or inability to sit upright for 30 to 60 minutes post-dose, documented severe upper GI intolerance, and Barrett esophagus. Each contraindication needs a chart note or lab result attached to the PA.

A 2022 Cochrane review comparing denosumab and bisphosphonates found denosumab produced modestly greater BMD gains at the lumbar spine and hip, but direct head-to-head fracture endpoint data remain limited. That review supports clinical arguments for denosumab superiority in specific patient subgroups, which can be cited when arguing that bisphosphonate therapy is inadequate.

The PA Submission Process

The prescriber (typically an endocrinologist, rheumatologist, or primary care physician) submits the PA to MDwise either through the MDwise provider portal or by fax using the MDwise PA request form. Indiana Medicaid requires MCOs to respond to standard PA requests within 3 business days and expedited requests within 24 hours when a delay would seriously jeopardize the member's health. If Prolia is needed urgently because the patient has already started it and stopping creates rebound risk (see the section on discontinuation below), an expedited request is clinically justified.

What Happens If MDwise Denies Prolia Coverage

Denial is not the end. Indiana Medicaid members have multiple appeal pathways, and reversal rates for well-documented medication appeals are meaningful.

Internal Appeal (First Level)

After a denial, the member or the prescriber acting as their authorized representative has 30 calendar days (or 10 days for expedited) to file an internal appeal with MDwise. The appeal should include:

• The full PA documentation already submitted
• A letter of medical necessity from the prescribing physician citing specific clinical data (DXA T-score, fracture history, FRAX score, bisphosphonate intolerance documentation)
• Peer-reviewed literature. The FREEDOM trial data (Cummings SR et al., NEJM 2009) and the AACE 2020 clinical practice guidelines (Camacho PM et al., Endocr Pract. 2020) are the two most persuasive documents to attach
• Lab results confirming the patient's renal function, calcium levels, and any contraindications to bisphosphonates

External Review and State Fair Hearing

If MDwise upholds the denial at the internal level, the member may request a state fair hearing through Indiana's FSSA Office of Hearings and Appeals. Indiana law, consistent with federal Medicaid requirements under 42 CFR § 431.220, entitles members to a fair hearing before any previously authorized service is terminated. This pathway has teeth: an administrative law judge can order MDwise to cover the drug.

Concurrently, the member may request an external independent medical review. Indiana requires MCOs to comply with external review determinations that favor the member.

Peer-to-Peer Review

Before filing a formal appeal, the prescribing physician can request a peer-to-peer call with a MDwise medical director. This call is often the fastest path to reversal. The physician should prepare to cite specific guideline language. The AACE guideline states that "denosumab is recommended as a first-line therapy for patients at very high risk for fracture," and this direct quotation from a named major guideline carries weight with a plan's medical director (Camacho PM et al., Endocr Pract. 2020).

Why Stopping Prolia Without a Transition Plan Is Dangerous

This is a clinical point that belongs in every PA and appeal letter when the patient is already on Prolia. Discontinuing denosumab without transitioning to a bisphosphonate causes rapid bone loss and a dramatically elevated risk of multiple vertebral fractures. A 2017 study in Osteoporosis International (Rossini M et al.) documented vertebral fracture incidence as high as 7.1% within 7 to 12 months of stopping denosumab, with some patients sustaining three or more new fractures in rapid succession.

The Endocrine Society clinical guidance recommends transitioning to a bisphosphonate (commonly zoledronic acid 5 mg IV, given once or twice, or alendronate) after stopping Prolia to preserve the BMD gains. This post-Prolia rebound risk is a medically compelling argument for continuity of coverage: denying a refill for a patient already on Prolia is clinically more dangerous than denying a new start.

MDwise coverage decisions that would interrupt an established Prolia regimen may be appealed on urgent or expedited timelines precisely because of this rebound fracture risk. Include the Rossini 2017 data and the Endocrine Society guidance in any such appeal.

Cost, Patient Assistance, and Coverage Gaps

List Price and Medicaid Reimbursement

Prolia's wholesale acquisition cost is approximately $1,940, $2,150 per 60 mg syringe as of 2024. For most MDwise members, if approved, the medication is available at a nominal Medicaid copay (Indiana Medicaid copays are $3 for preferred brand drugs for most eligible categories). The financial barrier to access, when one exists, is almost always coverage denial rather than copay cost.

Amgen FIRST STEP Program

For patients who are uninsured or underinsured and cannot get MDwise to cover Prolia, Amgen's FIRST STEP patient support program provides free or reduced-cost Prolia. Eligibility is income-based. The Amgen Safety Net Foundation and the program's enrollment line can be reached through the prescriber's office. This is a bridge while an appeal is pending, not a permanent solution, because continuity of every-six-month dosing matters for fracture prevention.

Calcium and Vitamin D: Always Covered

MDwise covers over-the-counter calcium carbonate and vitamin D3 supplements when prescribed, and these are required adjuncts to Prolia therapy. The NIH Office of Dietary Supplements recommends 600 to 800 IU vitamin D daily for adults over 70, with many bone specialists prescribing 1,000 to 2,000 IU to maintain 25-OH vitamin D above 30 ng/mL. Documenting that the patient is on adequate calcium and vitamin D is required for most Prolia PA submissions.

Interpreting DXA Results for MDwise Coverage Purposes

MDwise's PA criteria hinge heavily on DXA results. Understanding how DXA T-scores translate to coverage eligibility prevents avoidable denials.

T-Score Thresholds

The World Health Organization defines osteoporosis as a T-score at or below -2.5 at the lumbar spine, total hip, or femoral neck (WHO Technical Report, 1994). A T-score between -1.0 and -2.5 is osteopenia. Most MDwise PA criteria require a T-score at or below -2.5 OR a T-score at or below -2.0 combined with a fragility fracture history or a FRAX 10-year probability above a plan-specific threshold (commonly 20% for major osteoporotic fracture or 3% for hip fracture, per National Osteoporosis Foundation Clinician's Guide).

FRAX Calculation

FRAX (Fracture Risk Assessment Tool) is a free online calculator developed by the WHO Collaborating Centre for Metabolic Bone Diseases that integrates age, sex, BMI, and clinical risk factors to generate 10-year fracture probability. When the DXA T-score alone does not meet the coverage threshold, a FRAX calculation showing elevated 10-year risk can justify coverage under most MDwise PA criteria. The prescriber should print and attach the FRAX output to the PA submission.

Monitoring DXA After Starting Prolia

The American College of Radiology and major endocrine societies recommend repeat DXA 1 to 2 years after starting Prolia to document treatment response. If a follow-up DXA shows continued bone loss despite Prolia, that finding supports either a dose review or consideration of an anabolic agent such as teriparatide or romosozumab, which carry their own separate PA requirements under MDwise.

Practical Steps for Patients and Prescribers

Before Submitting the PA

1. Pull the most recent DXA report and confirm the T-score is documented at the relevant skeletal site (lumbar spine L1-L4, total hip, or femoral neck).
2. Calculate FRAX if the T-score is between -2.0 and -2.5.
3. Document bisphosphonate trial history or contraindications in the chart note.
4. Confirm serum calcium and creatinine are current (within 3 to 6 months).
5. Confirm calcium and vitamin D supplementation is prescribed.

After a Denial

Request the denial notice in writing. MDwise is required to provide the specific clinical criteria used to deny the request. Compare those criteria against the patient's actual chart. In many cases, the denial results from missing documentation rather than a genuine clinical disagreement. Resubmit with the missing piece before escalating to a formal appeal.

If the denial cites step therapy and the patient has a documented contraindication to bisphosphonates, attach the relevant FDA contraindication language for alendronate (renal impairment, esophageal abnormalities) alongside the patient's lab results or specialist note. A 2019 meta-analysis in JAMA Internal Medicine (Black DM et al.) confirmed that in patients with severe renal impairment, bisphosphonate safety profiles shift substantially, supporting denosumab as an appropriate alternative.

Patients in Indiana who believe their MCO has wrongly denied a medically necessary service may also contact the Indiana Patient Advocate Foundation or file a complaint with the Indiana Department of Insurance, which oversees MCO compliance with state managed care contracts.